Abstract
Radioactive tracers have made an immense contribution to the understanding of human physiology and pathology. At the start of the 21st century nuclear imaging has emerged as the main metabolic imaging modality which is of growing importance in drug development and clinical pharmacology. Using techniques adapted from those undertaken in clinical radiopharmacy and nuclear medicine facilities drug molecules and carrier systems may be radiolabelled and their release, biodistribution and uptake may be visualized in human subjects. Imaging studies are capable of locating the uptake of specific receptors in the brain, the site of disintegration of a tablet in the GI tract, the penetration of a nebulized solution into the lung and the residence time of an eye drop on the cornea. The technology uses suitable gamma emitting radionuclides such as 99mTc, 111In, 123I and 153Sm, which may be imaged with a gamma camera or positron emitters such as 11C, 13N, 15O and 18F for positron emission tomography (PET). Positron emitters are more appropriate for the direct labeling of drug molecules rather than metals such a 99mTc or 111In. A particular asset of these techniques is that the in vivo distribution and kinetics of a radiolabelled pharmaceutical formulation may be quantified. In this way correlation between the observed pharmacological effects and the precise site of delivery may be made. A powerful feature of nuclear molecular imaging is the evaluation of drug delivery systems in patient groups for whom the treatment is intended. Such studies not only provide data on the nature and characteristics of a product, such as reliability and reproducibility, but can demonstrate proof of principle for the new generation of targeted therapeutics. Imaging data are increasingly being used in product registration dossiers for submission to Regulatory Authorities.
Keywords: radiolabelled drugs, drug biodistribution, nuclear medicine
Current Pharmaceutical Design
Title: Radionuclide Imaging in Drug Development
Volume: 10 Issue: 24
Author(s): Alan C. Perkins and Malcolm Frier
Affiliation:
Keywords: radiolabelled drugs, drug biodistribution, nuclear medicine
Abstract: Radioactive tracers have made an immense contribution to the understanding of human physiology and pathology. At the start of the 21st century nuclear imaging has emerged as the main metabolic imaging modality which is of growing importance in drug development and clinical pharmacology. Using techniques adapted from those undertaken in clinical radiopharmacy and nuclear medicine facilities drug molecules and carrier systems may be radiolabelled and their release, biodistribution and uptake may be visualized in human subjects. Imaging studies are capable of locating the uptake of specific receptors in the brain, the site of disintegration of a tablet in the GI tract, the penetration of a nebulized solution into the lung and the residence time of an eye drop on the cornea. The technology uses suitable gamma emitting radionuclides such as 99mTc, 111In, 123I and 153Sm, which may be imaged with a gamma camera or positron emitters such as 11C, 13N, 15O and 18F for positron emission tomography (PET). Positron emitters are more appropriate for the direct labeling of drug molecules rather than metals such a 99mTc or 111In. A particular asset of these techniques is that the in vivo distribution and kinetics of a radiolabelled pharmaceutical formulation may be quantified. In this way correlation between the observed pharmacological effects and the precise site of delivery may be made. A powerful feature of nuclear molecular imaging is the evaluation of drug delivery systems in patient groups for whom the treatment is intended. Such studies not only provide data on the nature and characteristics of a product, such as reliability and reproducibility, but can demonstrate proof of principle for the new generation of targeted therapeutics. Imaging data are increasingly being used in product registration dossiers for submission to Regulatory Authorities.
Export Options
About this article
Cite this article as:
Perkins C. Alan and Frier Malcolm, Radionuclide Imaging in Drug Development, Current Pharmaceutical Design 2004; 10 (24) . https://dx.doi.org/10.2174/1381612043383476
DOI https://dx.doi.org/10.2174/1381612043383476 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis of 1,3,6-Trioxygenated Prenylated Xanthone Derivatives as Potential Antitumor Agents
Letters in Organic Chemistry Recent Patents Involving Virus Nucleotide Sequences; Host Defense, RNA Silencing and Expression Vector Strategies
Recent Patents on DNA & Gene Sequences Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Intranasal Drug Delivery for Brain Targeting
Current Drug Delivery Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Natural Monoclonal Antibodies and Cancer
Recent Patents on Anti-Cancer Drug Discovery Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Chest Pain in Children
Current Pediatric Reviews Percutaneous Dilatational Tracheostomy - An Update
Current Respiratory Medicine Reviews Editorial (Hot Topic: Exploring Molecular and Clinical Management of Patients in the Follow Up of the HPV Related Uterine Lesions)
Current Pharmaceutical Design A General Method for the Synthesis of 3,3-bis(indol-3-yl)indolin-2-ones, bis(indol-3-yl)(aryl)methanes and tris(indol-3-yl)methanes Using Naturally Occurring Mandelic Acid as an Efficient Organo-catalyst in Aqueous Ethanol at Room Temperature
Current Green Chemistry Advances in Research on the Preparation and Biological Activity of Maslinic Acid
Mini-Reviews in Medicinal Chemistry Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Coumarin Hybrids: Promising Scaffolds in the Treatment of Breast Cancer
Mini-Reviews in Medicinal Chemistry